

Eleonora Cocco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4252958/publications.pdf>

Version: 2024-02-01

246
papers

6,558
citations

76196

40
h-index

114278

63
g-index

253
all docs

253
docs citations

253
times ranked

7388
citing authors

#	ARTICLE	IF	CITATIONS
1	What happens after fingolimod discontinuation? A multicentre real-life experience. <i>Journal of Neurology</i> , 2022, 269, 796-804.	1.8	10
2	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	1.8	10
3	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	1.4	13
4	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
5	A real-world study of alemtuzumab in a cohort of Italian patients. <i>European Journal of Neurology</i> , 2022, 29, 257-266.	1.7	15
6	Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil. <i>Experimental Neurology</i> , 2022, 347, 113906.	2.0	6
7	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. <i>Neurology and Therapy</i> , 2022, 11, 39-49.	1.4	12
8	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	1.7	8
9	COVID-19 Severity in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	57
10	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	2.8	6
11	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. <i>Frontiers in Immunology</i> , 2022, 13, 818325.	2.2	5
12	The impact of secondary infections in COVID-19 critically ill patients. <i>Journal of Infection</i> , 2022, 84, e116-e117.	1.7	8
13	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	1.4	3
14	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. <i>Brain</i> , 2022, 145, 2796-2805.	3.7	38
15	Inter-joint coordination during gait in people with multiple sclerosis: A focus on the effect of disability. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103741.	0.9	6
16	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. <i>Biomolecules</i> , 2022, 12, 677.	1.8	2
17	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. <i>EBioMedicine</i> , 2022, 80, 104042.	2.7	54
18	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103909.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2106-2111.	1.4	30
20	Cyclograms Reveal Alteration of Inter-Joint Coordination during Gait in People with Multiple Sclerosis Minimally Disabled. <i>Biomechanics</i> , 2022, 2, 331-341.	0.5	3
21	Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104004.	0.9	9
22	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021, 28, 567-578.	1.7	6
23	<i>PRF1</i> mutation alters immune system activation, inflammation, and risk of autoimmunity. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1332-1340.	1.4	13
24	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	1.4	19
25	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
26	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	48
27	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	2.1	9
28	What gait features influence the amount and intensity of physical activity in people with multiple sclerosis?. <i>Medicine (United States)</i> , 2021, 100, e24931.	0.4	7
29	Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. <i>Neurological Sciences</i> , 2021, 42, 5177-5181.	0.9	1
30	Event-related potentials and deep grey matter atrophy in multiple sclerosis: Exploring the possible associations with cognition. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102785.	0.9	6
31	Kinematic Analysis of Lower Limb Joint Asymmetry During Gait in People with Multiple Sclerosis. <i>Symmetry</i> , 2021, 13, 598.	1.1	11
32	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.3	9
33	An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1993-2004.	2.0	15
34	Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers. <i>Frontiers in Neurology</i> , 2021, 12, 636463.	1.1	1
35	Active elderly and health can moderate exercise improve health and wellbeing in older adults? Protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 331.	0.7	26
36	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26

#	ARTICLE	IF	CITATIONS
37	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
38	Use of wrist-worn accelerometers to quantify bilateral upper limb activity and asymmetry under free-living conditions in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103081.	0.9	7
39	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 224.	1.0	2
40	The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. <i>Frontiers in Neurology</i> , 2021, 12, 679355.	1.1	2
41	Moderate Exercise Improves Cognitive Function in Healthy Elderly People: Results of a Randomized Controlled Trial. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 75-80.	0.6	35
42	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	2.7	184
43	EDSS trajectories in multiple sclerosis patients from the Italian MS register. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117824.	0.3	0
44	Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World. <i>Frontiers in Immunology</i> , 2021, 12, 728677.	2.2	7
45	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117749.	0.3	0
46	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDIatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110590.	0.5	1
47	Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 781843.	2.2	42
48	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. <i>Disability and Rehabilitation</i> , 2020, 42, 737-742.	0.9	6
49	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	0.9	14
50	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	2.1	39
51	Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , 2020, 29, 783-791.	1.5	4
52	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101886.	0.9	3
53	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1297-1303.	0.9	27
54	Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8848.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study. PLoS ONE, 2020, 15, e0236090.	1.1	26
56	Timed Up and Go in men and women with Multiple Sclerosis: Effect of muscular strength. Journal of Bodywork and Movement Therapies, 2020, 24, 124-130.	0.5	9
57	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirms group. Multiple Sclerosis and Related Disorders, 2020, 45, 102394.	0.9	2
58	The effect of a telerehabilitation virtual reality intervention on functional upper limb activities in people with multiple sclerosis: a study protocol for the TEAMS pilot randomized controlled trial. Trials, 2020, 21, 713.	0.7	14
59	Prevalence of Huntington's disease in Southern Sardinia, Italy. Parkinsonism and Related Disorders, 2020, 80, 54-57.	1.1	7
60	Walking in multiple sclerosis improves with tDCS: a randomized, double-blind, sham-controlled study. Annals of Clinical and Translational Neurology, 2020, 7, 2310-2319.	1.7	30
61	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. Journal of the Neurological Sciences, 2020, 417, 117064.	0.3	1
62	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	3.7	53
63	Cladribine vs other drugs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	32
64	Bipolar disorders and deep grey matter in multiple sclerosis: A preliminary quantitative MRI study. Multiple Sclerosis and Related Disorders, 2020, 46, 102564.	0.9	5
65	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurological Sciences, 2020, 41, 3185-3193.	0.9	15
66	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102145.	0.9	6
67	Delta-Globin Gene Expression Is Enhanced in vivo by Interferon Type I. Frontiers in Medicine, 2020, 7, 163.	1.2	1
68	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	0.9	4
69	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing-Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	1.0	22
70	The Use of Social Media and Digital Devices Among Italian Neurologists. Frontiers in Neurology, 2020, 11, 583.	1.1	18
71	The impact of deep grey matter volume on cognition in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102351.	0.9	11
72	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	0.9	6

#	ARTICLE	IF	CITATIONS
73	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	0.9	0
74	IL-2 and Mycobacterial Lipoarabinomannan as Targets of Immune Responses in Multiple Sclerosis Patients. <i>Microorganisms</i> , 2020, 8, 500.	1.6	6
75	Gait and Functional Mobility in Multiple Sclerosis: Immediate Effects of Transcranial Direct Current Stimulation (tDCS) Paired With Aerobic Exercise. <i>Frontiers in Neurology</i> , 2020, 11, 310.	1.1	21
76	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	1.4	36
77	Is There Any Relationship between Upper and Lower Limb Impairments in People with Multiple Sclerosis? A Kinematic Quantitative Analysis. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-6.	0.4	6
78	Getting older, getting worse: menopause as a turning-point for women living with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1192-1192.	0.9	0
79	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019, 266, 3098-3107.	1.8	1
80	Outcomes after fingolimod to alemtuzumab treatment shift in relapsing/remitting MS patients: a multicentre cohort study. <i>Journal of Neurology</i> , 2019, 266, 2440-2446.	1.8	16
81	“Better explanations” in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.5	44
82	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. <i>Neurotherapeutics</i> , 2019, 16, 797-807.	2.1	17
83	Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 1405-1411.	1.8	31
84	The Relationships between Physical Activity, Self-Efficacy, and Quality of Life in People with Multiple Sclerosis. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2019, 9, 121.	1.0	23
85	Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach. <i>PLoS ONE</i> , 2019, 14, e0226162.	1.1	12
86	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. <i>PLoS ONE</i> , 2019, 14, e0226615.	1.1	6
87	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. <i>Journal of Neurology</i> , 2019, 266, 707-716.	1.8	14
88	Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case-control MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 74-78.	0.9	20
89	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. <i>Multiple Sclerosis Journal</i> , 2019, 25, 23-30.	1.4	11
90	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study. <i>Journal of Neurology</i> , 2018, 265, 1096-1101.	1.8	14

#	ARTICLE	IF	CITATIONS
91	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 104-108.	0.9	9
92	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 8-11.	0.9	9
93	Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. <i>European Journal of Neurology</i> , 2018, 25, 1063-1068.	1.7	6
94	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.5	102
95	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.5	74
96	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. <i>Journal of Neurology</i> , 2018, 265, 424-430.	1.8	21
97	Long-term follow-up more than 10 years after HSCT: a monocentric experience. <i>Journal of Neurology</i> , 2018, 265, 410-416.	1.8	10
98	Cognition in multiple sclerosis: Between cognitive reserve and brain volume. <i>Journal of the Neurological Sciences</i> , 2018, 386, 19-22.	0.3	24
99	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. <i>Work</i> , 2018, 60, 263-270.	0.6	30
100	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. <i>Journal of Neurology</i> , 2018, 265, 1328-1333.	1.8	15
101	Adult brain volume in multiple sclerosis: The impact of paediatric onset. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 103-107.	0.9	10
102	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	1.8	23
103	Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial. <i>Disability and Rehabilitation</i> , 2018, 40, 144-151.	0.9	21
104	The burden of multiple sclerosis and patients' coping strategies. <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 38-40.	0.8	25
105	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. <i>Multiple Sclerosis Journal</i> , 2018, 24, 231-233.	1.4	3
106	Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation. <i>Neurological Sciences</i> , 2018, 39, 389-390.	0.9	3
107	Validation of the Arm Profile Score in assessing upper limb functional impairments in people with multiple sclerosis. <i>Clinical Biomechanics</i> , 2018, 51, 45-50.	0.5	10
108	Texting while walking differently alters gait patterns in people with multiple sclerosis and healthy individuals. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 129-133.	0.9	18

#	ARTICLE	IF	CITATIONS
109	PML in a person with multiple sclerosis. <i>Neurology</i> , 2018, 90, 83-85.	1.5	23
110	Brain volume in early MS patients with and without IgG oligoclonal bands in CSF. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 55-58.	0.9	2
111	Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers. <i>BMC Neurology</i> , 2018, 18, 212.	0.8	24
112	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 83-87.	0.9	9
113	Clinical activity after fingolimod cessation: disease reactivation or rebound?. <i>European Journal of Neurology</i> , 2018, 25, 1270-1275.	1.7	56
114	New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1093-1099.	1.0	15
115	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. <i>BMC Neurology</i> , 2018, 18, 67.	0.8	27
116	Association between brain atrophy and cognitive motor interference in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 208-211.	0.9	10
117	Top-down proteomic profiling of human saliva in multiple sclerosis patients. <i>Journal of Proteomics</i> , 2018, 187, 212-222.	1.2	40
118	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 1-6.	0.9	26
119	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
120	Overexpression of the Cytokine BAFF and Autoimmunity Risk. <i>New England Journal of Medicine</i> , 2017, 376, 1615-1626.	13.9	301
121	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017, 264, 973-978.	1.8	18
122	Charcot-Marie-Tooth disease: genetic subtypes in the Sardinian population. <i>Neurological Sciences</i> , 2017, 38, 1019-1025.	0.9	11
123	Cerebrospinal fluid analysis and the determination of oligoclonal bands. <i>Neurological Sciences</i> , 2017, 38, 217-224.	0.9	30
124	Do gait patterns differ in men and women with multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 202-208.	0.9	18
125	Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability. <i>Gait and Posture</i> , 2017, 58, 307-309.	0.6	39
126	â€˜Timed up and goâ€™™ and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 2201-2204.	1.8	13

#	ARTICLE	IF	CITATIONS
127	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 93, 148-155.	1.2	44
128	Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. <i>Journal of Neuroimmunology</i> , 2017, 313, 89-91.	1.1	8
129	Assessing association of comorbidities with treatment choice and persistence in MS. <i>Neurology</i> , 2017, 89, 2222-2229.	1.5	50
130	Perception of risk and shared decision making process in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 173-180.	1.4	13
131	TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy. <i>Current Medical Imaging</i> , 2017, 14, 95-98.	0.4	0
132	Effects of Six Months Training on Physical Capacity and Metaboreflex Activity in Patients with Multiple Sclerosis. <i>Frontiers in Physiology</i> , 2016, 7, 531.	1.3	10
133	Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon- β Therapy in Multiple Sclerosis Patients. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 91-93.	1.1	8
134	¹ H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e185.	3.1	68
135	Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients. <i>Scientific Reports</i> , 2016, 6, 22401.	1.6	42
136	The Required Coefficient of Friction for evaluating gait alterations in people with Multiple Sclerosis during gait. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 174-178.	0.9	6
137	History of multiple sclerosis in 2 successive pregnancies. <i>Neurology</i> , 2016, 87, 1360-1367.	1.5	16
138	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 187-191.	0.9	61
139	Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. <i>Scientific Reports</i> , 2016, 6, 29268.	1.6	18
140	Mitoxantrone exposure in pregnancy: a new case report in a multiple sclerosis patient. <i>Case Reports in Perinatal Medicine</i> , 2016, 5, 125-126.	0.1	4
141	Combining HLA-DRB1-DQB1 and Mycobacterium Avium Subspecies Paratuberculosis (MAP) antibodies in Sardinian multiple sclerosis patients: associated or independent risk factors?. <i>BMC Neurology</i> , 2016, 16, 148.	0.8	8
142	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 65-67.	0.9	5
143	Assessing response to interferon- β in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.5	98
144	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β 1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016, 22, 1163-1173.	1.4	24

#	ARTICLE	IF	CITATIONS
145	Alentuzumab long-term immunologic effect. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e194.	3.1	65
146	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	2.4	13
147	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. <i>PLoS ONE</i> , 2016, 11, e0163313.	1.1	15
148	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204.	0.8	31
149	Oral Agents in Multiple Sclerosis. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2015, 14, 15-25.	1.1	4
150	Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 759.	0.9	10
151	Induction and Escalation Therapies in Multiple Sclerosis. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2015, 14, 26-34.	1.1	20
152	Effectiveness and Limitations of Unsupervised Home-Based Balance Rehabilitation with Nintendo Wii in People with Multiple Sclerosis. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	22
153	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 132.	3.1	18
154	Role of interferon-beta in <i>Mycobacterium avium</i> subspecies paratuberculosis antibody response in Sardinian MS patients. <i>Journal of the Neurological Sciences</i> , 2015, 349, 249-250.	0.3	12
155	Attitude towards physical activity in patients with multiple sclerosis: a cohort study. <i>Neurological Sciences</i> , 2015, 36, 889-893.	0.9	19
156	Walking improvements with nabiximols in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2472-2477.	1.8	40
157	Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2015, 280, 66-68.	1.1	29
158	Progressive multiple sclerosis and mood disorders. <i>Neurological Sciences</i> , 2015, 36, 1625-1631.	0.9	14
159	Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 358, 339-344.	0.3	57
160	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. <i>Neurological Sciences</i> , 2015, 36, 2213-2220.	0.9	1
161	Relationship between gait initiation and disability in individuals affected by multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 594-597.	0.9	8
162	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. <i>Journal of the Neurological Sciences</i> , 2015, 357, 229-234.	0.3	6

#	ARTICLE	IF	CITATIONS
163	The burden of multiple sclerosis variants in continental Italians and Sardinians. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1385-1395.	1.4	10
164	Influence of treatments in multiple sclerosis disability: A cohort study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 433-441.	1.4	32
165	Human interferon regulatory factor 5 homologous epitopes of Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis induce a specific humoral and cellular immune response in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 984-995.	1.4	37
166	The current role of mitoxantrone in the treatment of multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 607-616.	1.4	36
167	Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35-55, in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2014, 347, 78-81.	0.3	10
168	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. <i>Muscle and Nerve</i> , 2014, 49, 928-930.	1.0	13
169	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171.	0.8	99
170	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. <i>Neurological Sciences</i> , 2014, 35, 401-408.	0.9	19
171	Antigenic peptide molecular recognition by the DRB1-DQB1 haplotype modulates multiple sclerosis susceptibility. <i>Molecular BioSystems</i> , 2014, 10, 2043-2054.	2.9	24
172	Novel characterization of gait impairments in people with multiple sclerosis by means of the gait profile score. <i>Journal of the Neurological Sciences</i> , 2014, 345, 159-163.	0.3	52
173	Long-term benefits of induction therapy in NMO: a case report. <i>Neurological Sciences</i> , 2014, 35, 1831-1832.	0.9	2
174	The risk of Bipolar Disorders in Multiple Sclerosis. <i>Journal of Affective Disorders</i> , 2014, 155, 255-260.	2.0	61
175	Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 270, 51-55.	1.1	56
176	Antigenic epitopes of MAP2694 homologous to T-cell receptor gamma-chain are highly recognized in multiple sclerosis Sardinian patients. <i>Molecular Immunology</i> , 2014, 57, 138-140.	1.0	26
177	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. <i>Journal of Affective Disorders</i> , 2014, 167, 192-197.	2.0	40
178	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. <i>BMC Neurology</i> , 2013, 13, 177.	0.8	48
179	Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 335, 131-133.	0.3	24
180	EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls. <i>Journal of Neuroimmunology</i> , 2013, 264, 120-122.	1.1	25

#	ARTICLE	IF	CITATIONS
181	<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and multiple sclerosis in Sardinian patients: epidemiology and clinical features. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1437-1442.	1.4	31
182	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. <i>Neurological Sciences</i> , 2013, 34, 197-203.	0.9	3
183	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	0.9	20
184	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 961-963.	1.4	17
185	Muscle MRI in female carriers of emerinopathy. <i>European Journal of Neurology</i> , 2013, 20, e127.	1.7	1
186	Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. <i>Muscle and Nerve</i> , 2013, 48, 161-170.	1.0	21
187	Structural and Dynamical Insights on HLA-DR2 Complexes That Confer Susceptibility to Multiple Sclerosis in Sardinia: A Molecular Dynamics Simulation Study. <i>PLoS ONE</i> , 2013, 8, e59711.	1.1	43
188	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. <i>PLoS ONE</i> , 2013, 8, e59790.	1.1	25
189	Association of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 203-207.	0.5	22
190	Overlapping syndromes in laminopathies: a meta-analysis of the reported literature. <i>Acta Myologica</i> , 2013, 32, 7-17.	1.5	33
191	Are <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and Epstein-Barr virus triggers of multiple sclerosis in Sardinia?. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1181-1184.	1.4	31
192	Cortical Pathology in RRMS: Taking a Cue from Four Sisters. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-6.	0.4	2
193	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. <i>PLoS ONE</i> , 2012, 7, e41678.	1.1	38
194	Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy. <i>Neuromuscular Disorders</i> , 2012, 22, 152-158.	0.3	19
195	Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and Comorbidity. <i>PLoS ONE</i> , 2012, 7, e32487.	1.1	147
196	HLA-DRB1-DQB1 Haplotypes Confer Susceptibility and Resistance to Multiple Sclerosis in Sardinia. <i>PLoS ONE</i> , 2012, 7, e33972.	1.1	34
197	Cardiac involvement in patients with lamin A/C gene mutations: A cohort observation. <i>Muscle and Nerve</i> , 2012, 46, 187-192.	1.0	17
198	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. <i>Neurological Sciences</i> , 2012, 33, 863-867.	0.9	10

#	ARTICLE	IF	CITATIONS
199	Epidemiology of multiple sclerosis in south-western Sardinia. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1282-1289.	1.4	66
200	Association of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> with Multiple Sclerosis in Sardinian Patients. <i>PLoS ONE</i> , 2011, 6, e18482.	1.1	85
201	Managing MS in a changing treatment landscape. <i>Journal of Neurology</i> , 2011, 258, 728-739.	1.8	29
202	The cohort of the multiple sclerosis center of Cagliari. <i>Neurological Sciences</i> , 2011, 31, 309-312.	0.9	4
203	Aberrant splicing in the <i>LMNA</i> gene caused by a novel mutation on the polypyrimidine tract of intron 5. <i>Muscle and Nerve</i> , 2011, 43, 688-693.	1.0	10
204	Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin $\alpha 2$ chain gene: A chance association or a novel phenotype?. <i>Muscle and Nerve</i> , 2011, 44, 826-828.	1.0	32
205	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011, 77, 1887-1895.	1.5	68
206	Evolution of the phenotype in a family with an <i>LMNA</i> gene mutation presenting with isolated cardiac involvement. <i>Muscle and Nerve</i> , 2010, 41, 85-91.	1.0	16
207	Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by <i>LMNA</i> gene mutations. <i>Muscle and Nerve</i> , 2010, 41, 458-463.	1.0	44
208	Variants within the immunoregulatory <i>CBLB</i> gene are associated with multiple sclerosis. <i>Nature Genetics</i> , 2010, 42, 495-497.	9.4	164
209	A Novel Mutation in Lamin A/C Gene: Phenotype and Consequences on the Protein Structure and Flexibility. <i>SRX Biology</i> , 2010, 2010, 1-7.	0.0	2
210	Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1030-1036.	1.4	3
211	Variation within the <i>CLEC16A</i> gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. <i>Genes and Immunity</i> , 2009, 10, 15-17.	2.2	69
212	Muscle MRI findings in patients with an apparently exclusive cardiac phenotype due to a novel <i>LMNA</i> gene mutation. <i>Neuromuscular Disorders</i> , 2008, 18, 291-298.	0.3	24
213	Juvenile Multiple Sclerosis Similar to Type I Diabetes Mellitus has a Seasonality of Month of Birth which Differs from that in the General Population. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2008, 21, 473-7.	0.4	7
214	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1225-1233.	1.4	72
215	Efficacy and Safety of Quetiapine Treatment for Delusional Parasitosis. <i>Clinical Neuropharmacology</i> , 2008, 31, 310-312.	0.2	10
216	Oxcarbazepine-Induced Leukopenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2008, 20, 502-503.	0.9	7

#	ARTICLE	IF	CITATIONS
217	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 975-980.	1.4	23
218	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1068-1070.	1.4	53
219	Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1200-1202.	1.4	39
220	Familial effects on the clinical course of multiple sclerosis. <i>Neurology</i> , 2007, 68, 376-383.	1.5	77
221	Variation of the Myelin Oligodendrocyte Glycoprotein gene is not primarily associated with multiple sclerosis in the Sardinian population. <i>BMC Genetics</i> , 2007, 8, 25.	2.7	6
222	Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. <i>Leukemia</i> , 2006, 20, 2217-2218.	3.3	31
223	Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. <i>Journal of Neurology</i> , 2006, 253, 208-213.	1.8	12
224	A novel Cx32 mutation causes X-linked Charcot-Marie-Tooth disease with brainstem involvement and brain magnetic resonance spectroscopy abnormalities. <i>Neurological Sciences</i> , 2006, 27, 18-23.	0.9	35
225	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. <i>Annals of Neurology</i> , 2006, 59, 634-639.	2.8	69
226	Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation. <i>Neurology</i> , 2006, 66, 108-111.	1.5	24
227	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006, 12, 814-823.	1.4	206
228	HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 327-327.	0.9	36
229	Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. <i>Functional Neurology</i> , 2006, 21, 145-9.	1.3	3
230	Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon β 1B. <i>Journal of Neurology</i> , 2005, 252, 1420-1422.	1.8	7
231	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005, 26, s200-s203.	0.9	17
232	Vagal nerve stimulation effects on cerebellar tremor in multiple sclerosis. <i>Neurology</i> , 2005, 65, 490-490.	1.5	11
233	The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. <i>Human Molecular Genetics</i> , 2004, 13, 2919-2924.	1.4	41
234	PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. <i>Journal of Neurology</i> , 2004, 251, 1085-8.	1.8	11

#	ARTICLE	IF	CITATIONS
235	Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004, 25, s368-s370.	0.9	37
236	Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. <i>Annals of Hematology</i> , 2004, 83, 403-405.	0.8	29
237	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 143, 31-38.	1.1	12
238	A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 143, 120-123.	1.1	16
239	Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. <i>Lancet</i> , The, 2002, 359, 1461-1465.	6.3	112
240	Chromosome 7q21 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. <i>Journal of Neuroimmunology</i> , 2002, 125, 141-148.	1.1	23
241	Lack of evidence for a role of the myelin basic protein gene in multiple sclerosis susceptibility in Sardinian patients. <i>Journal of Neurology</i> , 2002, 249, 1552-1555.	1.8	6
242	Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. <i>Human Molecular Genetics</i> , 2001, 10, 2907-2916.	1.4	134
243	The contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs. <i>Annals of Neurology</i> , 2000, 47, 411-412.	2.8	7
244	ICAM-1 gene is not associated with multiple sclerosis in sardinian patients. <i>Journal of Neurology</i> , 2000, 247, 677-680.	1.8	14
245	Age at onset in multiple sclerosis. <i>Neurological Sciences</i> , 2000, 21, S825-S829.	0.9	65
246	Is multiple sclerosis severity a genetically influenced trait?. <i>Neurological Sciences</i> , 2000, 21, S843-S847.	0.9	5